GlycoMimetics, Inc. (GLYC)

US — Healthcare Sector

Peers: MLYS FHTX IVA DYN LIFE TRVI CUE ANTX BCAB ASMB SPRO ACHL TIL NLTX

Automate Your Wheel Strategy on GLYC

With Tiblio's Option Bot, you can configure your own wheel strategy including GLYC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol GLYC
Rev/Share 0.0008
Book/Share 52.3115
PB 0.004
Debt/Equity 0.0
CurrentRatio 2.2898
ROIC -0.0093

MktCap 13551741.0
FreeCF/Share -79.4545
PFCF -0.0026
PE -0.4595
Debt/Assets 0.0
DivYield 0
ROE -0.0346

Rating C+
Score 2
Recommendation Sell
P/E Score 1
DCF Score 4
P/B Score 5
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	GLYC	Cantor Fitzgerald	--	Overweight	--	--	March 21, 2025

News

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

GLYC
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fai.

image for news GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

GLYC
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors

image for news Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

About GlycoMimetics, Inc. (GLYC)

IPO Date 2014-01-10
Website https://www.glycomimetics.com
Industry Biotechnology
CEO Ms. Stephanie R. Irish CPA
Employees 4

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.